19908-48-6
Chemical Structure
Maackiain
Synonym(s): DL-Maackiain
- CAS No.: 19908-48-6
- Formula:C16H12O5
- Molecular Weight:284.27
IUPAC Name: (6aS,12aS)-6a,12a-dihydro-6H-[1,3]dioxolo[4',5':5,6]benzofuro[3,2-c]chromen-2-ol
InChIKey: HJZIUUTWDFVGOK-BDJLRTHQSA-N
SMILES: OC1=CC=C2OC[C@]3([H])C4=CC5=C(OCO5)C=C4O[C@]3([H])C2=C1
Biological Activity: Maackiain (DL-Maackiain) is an orally active multi-target inhibitor with anti-tumor activity and neuroprotective effects. Maackiain activates the AMPK, NLRP3 and Nrf2/HO-1 pathways, and inhibits key targets such as NF-κB, mTOR, MAO-B, NFATc1 and PKCδ, thereby precisely regulating processes including apoptosis, autophagy and pyroptosis. Maackiain also effectively inhibits microglial activation, osteoclast formation, and proliferation and invasion of tumor cells, and protects dopaminergic neurons from damage. Maackiain is applicable to the research of various diseases such as Alzheimer's disease, osteoporosis, sepsis and dengue fever[1][2][3][4][5][6][7][8][9]。
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Maackiain | 99.83% | Maackiain (DL-Maackiain) is an orally active multi-target inhibitor with anti-tumor activity and neuroprotective effects. Maackiain activates the AMPK, NLRP3 and Nrf2/HO-1 pathways, and inhibits key targets such as NF-κB, mTOR, MAO-B, NFATc1 and PKCδ, thereby precisely regulating processes including apoptosis, autophagy and pyroptosis. Maackiain also effectively inhibits microglial activation, osteoclast formation, and proliferation and invasion of tumor cells, and protects dopaminergic neurons from damage. Maackiain is applicable to the research of various diseases such as Alzheimer's disease, osteoporosis, sepsis and dengue fever。 | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Bai X, et al. Maackiain protects against sepsis via activating AMPK/Nrf2/HO-1 pathway. Int Immunopharmacol. 2022;108:108710. [Content Brief]
- [2]. Lu N, et al. Maackiain Prevents Amyloid-Beta-Induced Cellular Injury via Priming PKC-Nrf2 Pathway. Biomed Res Int. 2022;2022:4243210. Published 2022 Jun 22. [Content Brief]
- [3]. Liu Y, et al. Maackiain dampens osteoclastogenesis via attenuating RANKL-stimulated NF-κB signalling pathway and NFATc1 activity. J Cell Mol Med. 2020;24(21):12308-12317. [Content Brief]
- [4]. Huh JW, et al. Maackiain, a compound derived from Sophora flavescens, increases IL-1β production by amplifying nigericin-mediated inflammasome activation. FEBS Open Bio. 2020;10(8):1482-1491. [Content Brief]
- [5]. Yun T, et al. Maackiain Reduces Neuroinflammation by Modulating Inflammatory Signals in LPS-Induced In Vitro and In Vivo Models. J Microbiol Biotechnol. 2026;36:e2508046. Published 2026 Feb 5. [Content Brief]
- [6]. He J, et al. Maackiain suppresses the development of cervical cancer via AMPK priming autophagy. J Pharm Pharmacol. 2024;76(1):23-33. [Content Brief]
- [7]. Aratanechemuge Y, et al. Induction of apoptosis by maackiain and trifolirhizin (maackiain glycoside) isolated from sanzukon (Sophora Subprostrate Chen et T. Chen) in human promyelotic leukemia HL-60 cells. Oncol Rep. 2004 Dec;12(6):1183-8. [Content Brief]
- [8]. Mizuguchi H, et al. Maackiain is a novel antiallergic compound that suppresses transcriptional upregulation of the histamine H1 receptor and interleukin-4 genes. Pharmacol Res Perspect. 2015;3(5):e00166. [Content Brief]
- [9]. Bezerra-Silva PC, et al. Extract of Bowdichia virgilioides and maackiain as larvicidal agent against Aedes aegypti mosquito. Exp Parasitol. 2015;153:160-164. [Content Brief]
Keywords
